Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation

A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients

“…[16][17][18][19] Telmisartan has the longest half-life of any ARB (approximately 24 hours) 20 and has been shown to reduce left ventricular hypertrophy (LVH) in clinical studies of hypertensive patients, [21][22][23][24] as well as in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan Randomized AssessmeNt Study in ACE-I iNtolerant subjects with cardiovascular Disease (TRANSCEND) cardiovascular (CV) outcomes, although no reduction in new-onset AF was found. [25][26][27] The purpose of the present study was to assess the efficacy of an antihypertensive therapeutic dose of telmisartan (80 mg once daily) as compared with that of the β-blocker carvedilol (25 mg once daily), which has been shown to have clinically important anti-arrhythmic properties, [28][29][30][31][32] for the prevention of AF recurrence in a population of hypertensive patients with a recent history of AF and who were in sinus rhythm and who did not require anti-arrhythmic therapy.…”

Letter by Banach et al Regarding Article, "Postoperative Treatment With Carvedilol, a β-Adrenergic Blocker, Prevents Paroxysmal Atrial Fibrillation After Coronary Artery Bypass Grafting"

“…[2][3][4][5] A study by Haghjoo et al demonstrated the efficacy of carvedilol on POAF, 2 and Meritt at al showed the significant advantage of postoperative carvedilol treatment vs metoprolol and atenolol. 3 The COMPACT trial is a large multicenter, randomized, controlled trial that is directly comparing oral carvedilol with oral metoprolol and will probably finally show whether there is a significant effect of carvedilol on POAF in patients following surgical coronary revascularization. 5 Unfortunately the study by Tsuboi et al 1 has many limitations that undermine their findings.…”

Carvedilol's antiarrhythmic properties: Therapeutic implications in patients with left ventricular dysfunction

“…5). 37 Carvedilol was compared with amiodarone in a placebo-controlled trial of patients with chronic AF undergoing electrical cardioversion. 38 Patients were randomized to receive carvedilol, amiodarone, or no antiarrhythmic drug for 6 weeks before and after external transthoracic cardioversion.…”